Core Viewpoint - The company is undergoing a capital increase for its subsidiary, Tongyuan Kang Biological, which will result in a significant reduction of its ownership stake and the subsidiary will no longer be a part of the group [1][2] Group 1: Capital Increase Details - The company and existing shareholders have entered into a capital increase agreement to raise approximately RMB 83.5 million, increasing the registered capital of Tongyuan Kang Biological from approximately RMB 14.0 million to about RMB 20.49 million [1] - Following the capital increase, the company's equity interest in Tongyuan Kang Biological will decrease from approximately 57.14% to 39.03% [1] - The capital increase is considered a disposal transaction due to the reduction in the company's shareholding [1] Group 2: Business Implications - Tongyuan Kang Biological is a biopharmaceutical company focused on dual antibodies, tri-antibodies, and ADC, operating independently from the group's core business [2] - The capital increase is expected to provide operational funding for Tongyuan Kang Biological, which is in its early stages and will require significant capital before commercialization [2] - The terms of the capital increase agreement were negotiated fairly and are based on normal commercial terms, considering the operational funding needs of Tongyuan Kang Biological and the contributions expected from investors [2]
同源康医药-B(02410.HK)：同源康生物引入若干投资者满足营运资金需求